Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.

ABSTRACT:

Aims

The present study aimed to evaluate the cost-effectiveness of the 5-day remdesivir regimen compared with standard of care among severe COVID-19 patients in China, the evidence on which is essential to inform the necessity of securing access to remdesivir.

Methods

A dynamic transmission model that extended the susceptible-exposed-infected-recovered framework by incorporating asymptomatic, presymptomatic and waiting-to-be-diagnosed patients was constructed to conduct the cost-effectiveness analysis from the healthcare system perspective. To estimate epidemic parameters, the model was first calibrated to the observed epidemic curve in Wuhan from 23 January to 19 March 2020. Following the calibration, the infected compartment was replaced by 3 severity-defined health states

SUBMITTER: Jiang Y 

PROVIDER: S-EPMC8251382 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature